99-MTC-TAT-BOMBESIN AS A NOVEL RADIOPHARMACEUTICAL FOR THE EARLY DETECTION OF BREAST CANCER.

摘要

The present invention refers to a novel radiopharmaceutical of Technetium-99m-N2S2-TAT (49- 57)-Lys3-Bombesin as an agent for the diagnosis of breast cancer by gammagraphic images, which is able to detect in vivo the overexpression of GRP receptors in MCF7 and MDA-MB231 cells of human breast cancer. Likewise, due to the internalization of the Tc-99m radionuclide into the PC-3 cells of prostate cancer and MCF7 and MDA-MB231 of breast cancer, the radiopharmaceutical may be used as a therapeutic agent. The purpose of the present invention is to provide a novel specific radiopharmaceutical (molecular target radiopharmaceutical) for a diagnosis and possible therapy of breast cancer, which is totally different from those currently available on the market.